Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tindara Franchina

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
Cancer Biology & Therapy|April 25, 2012
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: two case reportsTindara Franchina, Barbara Adamo, Giuseppina R R Ricciardi, et al.
Drugs - Real World Outcomes|September 16, 2021
Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance DatabaseMaria Antonietta Barbieri, Emanuela Elisa Sorbara, Giuseppe Cicala, et al.
Pharmaceuticals (Basel, Switzerland)|October 26, 2024
Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting SystemGiuseppe Cicala, Giulia Russo, Vincenza Santoro, et al.
European Journal of Clinical Pharmacology|March 17, 2025
Unveiling cardiovascular and respiratory toxicities with monoclonal antibodies in multiple myeloma: disproportionality analysis from the FDA Adverse Event Reporting SystemMaria Antonietta Barbieri, Giulia Russo, Giuseppe Cicala, et al.
Cancers|March 29, 2023
Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting SystemMaria Antonietta Barbieri, Emanuela Elisa Sorbara, Giulia Russo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 24, 2014
NSCLC and HER2: between lights and shadowsGiuseppina Rosaria Rita Ricciardi, Alessandro Russo, Tindara Franchina, et al.
Oncotarget|January 7, 2017
Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancerAlessandro Russo, Tindara Franchina, Giuseppina Rosaria Rita Ricciardi, et al.
Journal of Cellular Physiology|April 20, 2018
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or DocetaxelAlessandro Russo, Tindara Franchina, Giuseppina R R Ricciardi, et al.
Biomedicines|August 26, 2023
Renal Disorders with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System DatabaseGiulia Russo, Maria Antonietta Barbieri, Emanuela Elisa Sorbara, et al.
Plos One|July 3, 2015
Correction: Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) PatientsGiuseppina Rosaria Rita Ricciardi, Barbara Adamo, Antonio Ieni, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
Cancer Biology & Therapy|April 25, 2012
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: two case reportsTindara Franchina, Barbara Adamo, Giuseppina R R Ricciardi, et al.
Drugs - Real World Outcomes|September 16, 2021
Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance DatabaseMaria Antonietta Barbieri, Emanuela Elisa Sorbara, Giuseppe Cicala, et al.
Pharmaceuticals (Basel, Switzerland)|October 26, 2024
Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting SystemGiuseppe Cicala, Giulia Russo, Vincenza Santoro, et al.
European Journal of Clinical Pharmacology|March 17, 2025
Unveiling cardiovascular and respiratory toxicities with monoclonal antibodies in multiple myeloma: disproportionality analysis from the FDA Adverse Event Reporting SystemMaria Antonietta Barbieri, Giulia Russo, Giuseppe Cicala, et al.
Cancers|March 29, 2023
Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting SystemMaria Antonietta Barbieri, Emanuela Elisa Sorbara, Giulia Russo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 24, 2014
NSCLC and HER2: between lights and shadowsGiuseppina Rosaria Rita Ricciardi, Alessandro Russo, Tindara Franchina, et al.
Oncotarget|January 7, 2017
Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancerAlessandro Russo, Tindara Franchina, Giuseppina Rosaria Rita Ricciardi, et al.
Journal of Cellular Physiology|April 20, 2018
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or DocetaxelAlessandro Russo, Tindara Franchina, Giuseppina R R Ricciardi, et al.
Biomedicines|August 26, 2023
Renal Disorders with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System DatabaseGiulia Russo, Maria Antonietta Barbieri, Emanuela Elisa Sorbara, et al.
Plos One|July 3, 2015
Correction: Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) PatientsGiuseppina Rosaria Rita Ricciardi, Barbara Adamo, Antonio Ieni, et al.
Pageof 7